

# Association study of *AFF1* gene polymorphism (rs340630) with Iranian systemic lupus erythematosus patients

Arabi E<sup>1,3</sup>, Garshasbi M<sup>2</sup>, Jamshidi AR<sup>1</sup>, Khalesi R<sup>2</sup>, Ahmadzadeh N<sup>1</sup>, Akbarian M<sup>1</sup>, Mahmoudi M<sup>1</sup>

ACTA REUMATOL PORT. 2016;41:68-73

## ABSTRACT

**Aim:** To investigate whether *AFF1* polymorphism was associated with susceptibility and clinical features of SLE in Iranian patients.

**Methods:** A total of 320 patients with SLE and 330 age, sex and ethnically matched healthy control subjects were enrolled in the present study. Both cases and healthy controls were genotyped for rs340630 polymorphism located inside the *AFF1* using Amplification Refractory Mutation System-PCR (ARMS-PCR). In order to investigate the association of this SNP with clinical features of SLE, clinical manifestations of the patients were recorded. The distribution of rs340630 genotypes were tested for deviation from Hardy-Weinberg in healthy controls. Genotypic and allelic distribution between patients and controls were assessed by chi-square test.

**Major results:** Both A and G alleles of rs340630 were seen among our cohort of Iranian SLE and healthy control samples. All three genotypes of rs340630 were found, i.e., homozygous A/A (OR=1/01, 95%CI=%72 – 1/42, P=%99), homozygous G/G (OR=%92, 95%CI= %63 – 1/35, P=%77) and heterozygous A/G (OR=1/03, 95%CI= %76 – 1/41, P=%87). No significant differences were observed between allele frequency of this polymorphism in SLE patients and healthy controls. However, in the SLE group, the number of patients with renal disorder was significantly increased for the AG genotype compared to the other genotypes of *AFF1* polymorphism (P= 0.05).

**Conclusion:** There was no association between *AFF1* polymorphism (rs340630) and SLE. However, our

findings indicated that the AG genotype of *AFF1* polymorphism (rs340630) was significantly (P=0.0045) correlated with renal disorder in Iranian population.

**Keywords:** Systemic lupus erythematosus; Autoimmune rheumatic disease; Chronic immune diseases

## INTRODUCTION

Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease. It causes multiple organ damage with different clinical manifestations<sup>1,2</sup> ranging from mild cases with limited skin and joint manifestations to life-threatening conditions with renal impairment, severe cytopenia, central nervous system disease, or thromboembolic events<sup>3</sup>. This disease is characterized by autoantibodies to nuclear antigens, immune complex deposition, and subsequent tissue destruction<sup>4</sup>.

There are various reports from different parts of the world on the prevalence and characteristics of SLE. These reports have revealed that there are gender, age, and racial variations affecting the prevalence of SLE<sup>1,5</sup>. The SLE prevalence in the African-American, Spanish, and Asian population is higher than the Caucasian population<sup>6</sup>. Familial aggregation of the disease and studies on monozygotic twins have provided strong evidence to support the role of genetic factors along with environmental and hormonal factors in the pathogenesis of SLE<sup>4,7-9</sup>. Since the epidemiology of SLE has demonstrated that the prevalence of the disease substantially differs among populations, genetic backgrounds of SLE should be also heterogeneous across populations<sup>6,10</sup>. In addition to genetic differences across ethnicities, variations in the environment, culture, socioeconomic status, and methodological factors could also underlie the differences in the disease prevalence and manifestations among ethnic groups<sup>3,11,12</sup>.

1. Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran

2. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University Tehran, Iran

3. Department of Biology, Ahar Branch, Islamic Azad University, Ahar, Iran

Since 2008, more than 25 potential loci for SLE have been identified by genome wide association studies (GWASs) performed in Caucasian population<sup>13-24</sup>. The investigations have demonstrated that several genes associated with SLE in Caucasians are also risk factors in Asians: HLA-II, STAT4, BANK1, BLK, IRF5, TNFSF4, ITGAM, etc<sup>1</sup>. These risk alleles account for about 8–15% of the total genetic susceptibility to the disease<sup>23,25</sup>. Therefore, it is still important to examine the sub-loci of GWAS in order to reveal the entire picture of the genetic etiology<sup>3</sup>.

In a recent GWAS, a novel association has been detected between a variant in the AF4/FMR2 family, member 1 (AFF1) gene at 4q21, and SLE susceptibility (rs340630;  $P = 8.361029$ , OR = 1.21) in a Japanese population suggesting that AFF1 is involved in the etiology of SLE through the regulation of development and activity of lymphocytes. Their results showed that accumulation of quantitative changes in the gene expression would accelerate the onset of SLE<sup>26</sup>.

Therefore, in this study, the association of AFF1 polymorphism (rs340630) with susceptibility and clinical features of SLE in Iranian patients was investigated.

## PATIENTS AND METHODS

### SAMPLE COLLECTION

A total of 650 Iranians including 320 SLE patients (40 males and 280 females, mean  $\pm$  SD age  $36.96 \pm 12.025$  years) and 330 age, sex and ethnically matched healthy controls (42 males and 288 females, mean  $\pm$  SD age  $37.62 \pm 12.320$  years) without any signs or symptoms of autoimmune diseases were studied. SLE patients were recruited from the outpatient rheumatology clinic of Shariati Hospital, Tehran, Iran, from February 2012 to April 2014, and healthy controls participated in this study voluntarily at the same time. All the SLE patients met the 1997 American College of Rheumatology (ACR) revised classification criteria for SLE. The study was approved by the local ethics committee of Tehran University of Medical Sciences. Informed consent was obtained from all patients and healthy controls.

### DNA ANALYSIS

10-ml peripheral blood sample was collected from each participant and genomic DNA was extracted from the white blood cells (WBCs) using the phenol-chloroform method<sup>27</sup>. The quantity of the extracted DNA was measured at 280 nm wavelength by the Thermo 2000 Nano-

drop spectrophotometer.

### ARMS-PCR

SNP Genotyping was performed using Amplification Refractory Mutation System-PCR (ARMS-PCR) method. The PCR reaction was carried out in 20  $\mu$ l of the solution containing Taq DNA polymerase, standard 10x PCR buffer, 200 ng DNA, 0.2  $\mu$ M of each primer, 1.5mM of MgCl<sub>2</sub> and 200  $\mu$ M of dNTP mix and 0.5 U Taq polymerase. Cycling conditions was initial denaturation (94°C, 3 min) followed by 40 cycles at 94°C for 30 sec, 64°C for 30 sec, 72°C for 30 sec, and final extension at 72°C for 10 min. Both alleles were amplified in separated PCR reactions with allele specific primers for A and G alleles (Table I). The amplified DNA fragments were separated on 2% (w/v) agarose gel and viewed after staining with ethidium bromide. A 100 bp DNA ladder was used as a marker to estimate the size of the PCR products. The samples were genotyped and classified into one of the three possible genotypes AA, AG, GG. In order to confirm ARMS-PCR results, the DNA of 3 samples (one sample from each of the AA, AG and GG genotypes) was sequenced by the Sanger sequencing method and analyzed with the Codoncode Aligner software (Version. 6.0.2).

### STATISTICAL ANALYSIS

Statistical analyses were performed using SPSS V: 19 Software. Statistical calculations in this study included allelic and genotypic frequencies (n), Chi-square and odds ratio (OR). P values were calculated for each allele and genotype in the patient and control groups<sup>28</sup>. The genotype distributions of AFF1 (rs340630) were tested for deviation from the Hardy-Weinberg equilibrium in control group using  $\chi^2$  test in Package 'genetics' of R-Software, Version. R-3.2.0 (<http://cran.um.ac.ir/web/packages/genetics/genetics.pdf>). To adjust for multiple testing the Benjamini-Hochberg method<sup>29</sup> to control the False Discovery Rate (FDR) was used. P value of less than 0.05 was considered to be statistically significant.

### RESULTS

Two PCR products were observed on the agarose gel. The expected size of the normal and mutant alleles was 198 and 355 bps, respectively. Both A and G alle-

**TABLE I. PRIMERS AND AMPLICON SIZES USED IN THIS STUDY**

Name	Sequence	Amplicon Size (bp)
E.AFF1	5'-CCCAAAATCAGTTTTTCAGAGC-3'	434
R.AFF1	5'-AGAAGCTGCTTCAACCCAGGA-3'	
Rwt	5'-TTTGGGGAGCATTTTGTACC-3'	198
Rmt	5'-TTTGGGGAGCATTTTGTACT-3'	



**FIGURE 1.** ARMS-PCR gel electrophoresis for AFF1 A/G polymorphism in 7 samples. Samples 1 and 2 are heterozygote (AG), sample 3 is homozygote for A allele (AA) and samples 4-7 are homozygote for G allele (GG). Sample 8 is negative control. The expected size of internal control and allele specific products are 434 bp and 198 bp, respectively. B is an empty lane

**TABLE II. COMPARISON OF ALLELE AND GENOTYPE FREQUENCIES OF AFF1 POLYMORPHISMS (RS340630) IN THE SLE PATIENTS AND HEALTHY CONTROLS**

Alleles/Genotypes	SLE (n=320) N (%)	Control (n=330) N (%)	P	$\chi^2$	OR† (CI‡)
A	370 (56.6)	357 (54.9)	0.39	0.72	1.11 (89%-1.38)
G	270 (43.4)	303 (45.1)	0.54	0.36	0.092 (74%-1.15)
GG	64 (65.25)	70 (69.55)	0.77	0.81	0.092 (63%-1.35)
AG	161 (158.50)	163 (163.90)	0.87	0.24	1.03 (76%-1.41)
AA	95 (96.25)	97 (96.55)	0.99	0	1.01 (72%-1.42)
HWE§	P= 0.78	P= 0.92			

†OR, odds ratio, ‡CI, confidence interval; §HWE, Hardy-Weinberg Equilibrium

les of rs340630 were seen among the Iranian samples. All three genotypes of rs340630 were found, i.e., homozygous A/A, homozygous G/G and heterozygous A/G, as shown in Figure 1.

The genotypic and allelic frequency of AFF1 A/G polymorphism is shown in Table II. Genotypic distribution of this polymorphism did not deviate from that expected Hardy-Weinberg Equilibrium (HWE), and the heterozygous A/G genotype showed the highest frequency among both SLE (50.3%) and healthy control (49.3%) groups (Table II). Allele frequency of this poly-

morphism was not significantly different between SLE patients and healthy controls.

In addition, we investigated the association between this polymorphism and clinical manifestations of the SLE group using the Chi-square test (Table III). In the SLE group, the number of patients with renal disorder after adjusting for the Bonferroni multiple comparison correction was significantly higher for the AG genotype compared to the other genotypes of AFF1 polymorphism ( $P= 0.05$ ).

## DISCUSSION

**TABLE III. FREQUENCIES OF RS340630 GENOTYPES WITH VARIOUS CLINICAL FEATURES**

Clinical features	Number	Frequency N (%)			P-Value	Adj. P*
		rs340630 Genotypes distribution				
		AA (%)	AG (%)	GG (%)		
Photo sensitivity	205	56 (27.3)	107 (52.2)	42 (20.5)	0.753	0.82
Malar rash	111	30 (27)	54 (48.6)	27 (24.3)	0.610	0.82
Discoid rash	15	4 (26.7)	7 (46.7)	4 (26.7)	0.870	0.87
Oral ulcer	79	20 (25.3)	40 (50.6)	19 (24.1)	0.686	0.82
Arthritis	201	51 (25.4)	100 (49.8)	50 (24.9)	0.046	0.18
Pleuritis	52	17 (32.7)	26 (50.0)	9 (17.3)	0.594	0.82
Pericarditis	15	7 (46.7)	6 (40.0)	2 (13.3)	0.238	0.52
Serositis	19	4 (21.1)	13 (68.4)	2 (10.5)	0.262	0.52
Anti-ds DNA	261	69 (26.4)	136 (52.1)	56 (21.5)	0.022	0.13
ANA†	274	76 (27.7)	139 (50.7)	59 (21.5)	0.661	0.82
Renal disorder	120	19 (15.8)	73 (60.8)	28 (23.3)	0.0045	0.05
Hematologic disorder	176	55 (31.3)	86 (48.9)	35 (19.9)	0.233	0.52

\*FDR-adjusted Pvalue for multiple testing using the Benjamini-Hochberg method, †Anti-nuclear Antibody

Autoimmune diseases, such as SLE, are a varied group of complex disorders with a strong genetic component, caused by breakdown of self-tolerance<sup>30</sup>. Identification of genes involved in multifactorial diseases has been classically approached by association studies such as those conclusively demonstrating the presence of SLE susceptibility factors in the HLA region<sup>31,32</sup>.

SLE is a relatively common disorder with a prevalence of 40 per 100000 in Iran<sup>33</sup>. Relatively high prevalence<sup>32</sup>, high mortality rate (approximately 20.2%)<sup>34</sup>, clinical heterogeneity of the disease, and involvement of vital organs such as the brain, blood, and kidneys in most patients that are mostly women of child bearing age, necessitate efforts to develop diagnostic tools and effective therapies<sup>2</sup>. On the other hand, early detection by finding potential susceptibility genes and their molecular interactions may help to prevent its occurrence or progression and could provide targets for more focused therapies in SLE<sup>4,5</sup>.

Familial aggregation demonstrates that both genetic and environmental factors play an important role in the pathogenesis of SLE. Genetic studies have been performed using candidate gene approaches and recently, genome-wide association studies (GWAS). However, most of these studies have been conducted in European populations, and few studies have been performed in Asian populations<sup>35-37</sup> and especially the status of SLE in Iran has remained indistinct<sup>33</sup>. Since the

epidemiology of SLE has demonstrated that the prevalence of the disease substantially differs among populations, genetic backgrounds of SLE should also be heterogeneous across populations<sup>6,10,26</sup>.

In SLE, for example, the 26 risk loci identified by the previous GWASs explain only around 8% of the total genetic susceptibility to the disease. Therefore, it is still important to examine the sub-loci of GWAS in order to reveal the entire picture of genetic etiology<sup>23,26</sup>.

In a GWAS study performed in the Japanese population (2012), a novel association is found between AFF1 gene polymorphism at 4q21 and SLE susceptibility (rs340630;  $P = 8.361029$ ,  $OR = 1.21$ ). Because expression quantitative trait loci (eQTLs) have been implicated in genetic risks for autoimmune diseases, an eQTL study was integrated into the results of the GWAS. By this, it was confirmed that A allele of rs340630 had a cis-eQTL effect on the AFF1 transcript with enhanced expression levels ( $P = 0.05$ ). AFF1 transcripts are prominently expressed in CD4+ and CD19+ peripheral blood lymphocytes, up-regulation of AFF1 may cause abnormalities in these lymphocytes, and therefore leading to the disease onset<sup>26</sup>. Thus, we surveyed the association of this SNP with SLE in an Iranian population.

Surprisingly, our findings were contradictory to this GWAS study. In line with our findings, no association between rs340630 and SLE susceptibility was found in a Chinese population (for A versus G,  $P = 0.79$ ,  $OR 0.98$ ,

95% CI 0.86-1.12)<sup>38</sup>. The allelic distribution of AFF1 A/G polymorphism in the Iranian population was similar to what was found in the Chinese population but different from the Japanese population.

## CONCLUSION

In our present study, it was observed that the AFF1 polymorphism (rs340630) was correlated with renal disorder, a clinical feature observed in patients with SLE. Furthermore, our results showed that AFF1 polymorphism was not significantly associated with SLE susceptibility. Further studies on different genetic risk factors in various ethnics of Iran are warranted to shed more light on the genetic background of this disease in Iranian patients.

## CORRESPONDENCE TO

Mahmoudi M  
Rheumatology Research Center,  
Tehran University of Medical Sciences,  
Tehran, Iran  
E-mail: mahmoudim@tums.ac.ir

## REFERENCES

- Akbarian M. et al. Systemic lupus erythematosus in Iran: a study of 2280 patients over 33 years. *Int J Rheum Dis* 2010. 13(4): p. 374-349.
- Tsokos GC. Systemic lupus erythematosus. *N Engl J Med* 2011. 365(22): p. 2110-2121.
- Wang C. et al. Genes identified in Asian SLE GWASs are also associated with SLE in Caucasian populations. *Eur J Hum Genet* 2013. 21(9): p. 994-999.
- Kyogoku C, Tsuchiya N. A compass that points to lupus: genetic studies on type I interferon pathway. *Genes Immun* 2007. 8(6): p. 445-455.
- Chua KH et al. Genetic Polymorphisms of the Interleukin-1 beta (IL-1. BETA.)-511 and+ 3954 Single Nucleotide Polymorphisms (SNPs) in Malaysian Systemic Lupus Erythematosus (SLE) Patients. *Journal of Health Science* 2009. 55(4): p. 657-662.
- Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. *Lupus* 2006. 15(5): p. 308-318.
- Sestak AL et al. Familial aggregation of lupus and autoimmunity in an unusual multiplex pedigree. *J Rheumatol* 1999. 26(7): p. 1495-1499.
- Hahn BH. An overview of the pathogenesis of systemic lupus erythematosus. *Dubois' lupus erythematosus*, 1993. 5: p. 69-76.
- Mongey AB, Hess EV. The role of environment in systemic lupus erythematosus and associated disorders. *Dubois' lupus erythematosus*. 5th ed. Baltimore: Williams & Wilkins, 1997: p. 31-47.
- Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients. *Ann Rheum Dis*, 1994. 53(10): p. 675-680.
- Yamaguchi-Kabata Y et al. Japanese population structure, based on SNP genotypes from 7003 individuals compared to other ethnic groups: effects on population-based association studies. *Am J Hum Genet* 2008. 83(4): p. 445-456.
- Xia ZB et al. The MLL fusion gene, MLL-AF4, regulates cyclin-dependent kinase inhibitor CDKN1B (p27kip1) expression. *Proc Natl Acad Sci U S A* 2005. 102(39): p. 14028-14033.
- Sigurdsson S et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. *Am J Hum Genet* 2005. 76(3): p. 528-537.
- Graham RR et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. *Nat Genet*, 2006. 38(5): p. 550-555.
- Graham RR et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. *Proc Natl Acad Sci U S A* 2007. 104(16): p. 6758-6763.
- Remmers EF et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. *N Engl J Med* 2007. 357(10): p. 977-986.
- Graham DSC et al. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. *Nat Genet* 2008. 40(1): p. 83-89.
- Nath SK et al. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. *Nat Genet* 2008. 40(2): p. 152-154.
- Harley JB et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXX, KIAA1542 and other loci. *Nature genetics* 2008. 40(2): p. 204-210.
- Kozyrev SV et al. Functional variants in the B-cell gene BANK1 are associated with systemic lupus erythematosus. *Nat Genet* 2008. 40(2): p. 211-216.
- Hom G et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. *N Engl J Med* 2008. 358(9): p. 900-909.
- Musone SL et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. *Nat Genet* 2008. 40(9): p. 1062-1064.
- Gateva V et al. A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. *Nat Genet* 2009. 41(11): p. 1228-1233.
- Lessard CJ et al. Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. *Am J Hum Genet* 2011. 88(1): p. 83-91.
- Harley IT et al. Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies. *Nat Rev Genet* 2009. 10(5): p. 285-90.
- Okada Y et al. A genome-wide association study identified AFF1 as a susceptibility locus for systemic lupus erythematosus in Japanese. *PLoS Genet* 2012. 8(1): p. e1002455.
- Roe BA, Crabtree J, Khan A. Methods for DNA isolation. Part III. Protocols for recombinant DNA isolation, cloning, and sequencing [Internet edition]. Norman, OK: University of Oklahoma, 1995: p. 2488-2498.
- McPherson G. Applying and interpreting statistics: a comprehensive guide. 2001: Springer.
- Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)* 1995:

- p. 289-300.
30. Rose AM, Bell LC. Epistasis and immunity: the role of genetic interactions in autoimmune diseases. *Immunology* 2012. 137(2): p. 131-138.
  31. D'Alfonso S et al. Systemic lupus erythematosus candidate genes in the Italian population: evidence for a significant association with interleukin-10. *Arthritis Rheum* 2000. 43(1): p. 120-128.
  32. Rezaieyazdi Z et al. Association of HLA-DQB1 allelic sequence variation with susceptibility to systemic lupus erythematosus. *Iranian Journal of Allergy, Asthma and Immunology* 2008. 7(2): p. 91-95.
  33. Davatchi F et al. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. *The Journal of Rheumatology*, 2008. 35(7): p. 1384-1390.
  34. Yeap SS et al. Mortality patterns in Malaysian systemic lupus erythematosus patients. *Med J Malaysia* 2001. 56(3): p. 308-312.
  35. Han JW et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. *Nat Genet* 2009. 41(11): p. 1234-7.
  36. Yang W et al. Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus. *PLoS Genet* 2010. 6(2): p. e1000841.
  37. Yang J et al. ELF1 is associated with systemic lupus erythematosus in Asian populations. *Human Molecular Genetics* 2010.
  38. Cen H et al. Association of AFF1 rs340630 and AFF3 rs10865035 polymorphisms with systemic lupus erythematosus in a Chinese population. *Immunogenetics* 2012. 64(12): p. 935-938.